Hennion & Walsh Asset Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.63M Sell
7,712
-528
-6% -$104K 0.05% 437
2026
Q1
$1.61M Buy
8,240
+957
+13% +$186K 0.05% 396
2025
Q4
$1.26M Buy
7,283
+744
+11% +$135K 0.04% 466
2025
Q3
$1.25M Buy
6,539
+2,538
+63% +$450K 0.05% 462
2025
Q2
$719K Buy
4,001
+1,032
+35% +$179K 0.03% 574
2025
Q1
$502K Buy
2,969
+1,422
+92% +$234K 0.02% 629
2024
Q4
$233K Buy
1,547
+100
+7% +$15.6K 0.01% 807
2024
Q3
$225K Buy
+1,447
New +$216K 0.01% 810
2023
Q3
Sell
-3,409
Closed -$479K 813
2023
Q2
$479K Sell
3,409
-604
-15% -$83.3K 0.03% 515
2023
Q1
$568K Sell
4,013
-384
-9% -$54.9K 0.03% 480
2022
Q4
$688K Sell
4,397
-350
-7% -$50.3K 0.04% 420
2022
Q3
$582K Sell
4,747
-239
-5% -$31.5K 0.04% 451
2022
Q2
$663K Sell
4,986
-67
-1% -$9.13K 0.04% 423
2022
Q1
$692K Buy
5,053
+189
+4% +$26.3K 0.04% 439
2021
Q4
$842K Buy
4,864
+1,581
+48% +$241K 0.04% 414
2021
Q3
$477K Buy
+3,283
New +$480K 0.03% 521

Other funds holding DGX

Hennion & Walsh Asset Management's DGX Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its Quest Diagnostics (DGX) stake by 6.4% in Q2 2026, selling an estimated $104K and leaving 7,712 shares worth $1.63M. The position accounts for 0.05% of the portfolio, ranked #437.

Hennion & Walsh Asset Management first reported a position in DGX in Q3 2021 and has held it in 16 quarters since. 287 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Hennion & Walsh Asset Management held 7,712 shares of Quest Diagnostics worth $1.63M as of Q2 2026.
  • Hennion & Walsh Asset Management sold 528 Quest Diagnostics shares in Q2 2026, an estimated $104K.
  • Quest Diagnostics made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #437 holding.
  • Hennion & Walsh Asset Management first reported a position in Quest Diagnostics in Q3 2021 and has held it in 16 quarters since.
  • 287 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.